Endo International (ENDP) Tops Q2 EPS by 22c, Lifts FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
- Qualcomm shares fall on Intel warning and legal concerns
- Marvell Technology shares drop on Lumentum deal concerns
- Oracle shares drop on AI spending concerns and Microsoft criticism
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Broadcom shares drop amid chip sector selloff
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Endo Reports Second-Quarter 2018 Financial Results
August 8, 2018 7:00 AM EDTDUBLIN, Aug. 8, 2018 /PRNewswire/ --
Second-quarter 2018 revenues of $715 million compared to second-quarter 2017 revenues of $876 million Second-quarter 2018 XIAFLEX® franchise revenues increased 27 percent versus second-quarter 2017 to $64 million Second-quarter 2018 Sterile Injectables revenues increased 21 percent versus second-quarter 2017 to $218 million Entered exclusive licensing agreement with Nevakar for the development of five 505(b)(2) injectable products Company raises 2018 financial guidance Phase 3 trials for collagenase clostridium histolyticum (CCH) for the treatment of cellulite now expected to have... More


